SCHEMBL24258021

SCHEMBL24258021

O=c1ccc(-c2noc(Cc3cccc(Cl)c3)n2)c[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.48
ERCC4 Q92889 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
MAPK1 P28482 4/20 0.47
KMT2A Q03164 3/20 0.47
RAB9A P51151 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
PLAT P00750 1/20 0.47
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 2/20 0.44
TSHR P16473 3/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 2/20 0.44
RXFP1 Q9HBX9 1/20 0.43
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258072 0.85 MAPK1 (0.58) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL24258084 0.85 S1PR1 (0.58) SMN1; SMN2MAPK1KMT2ARAB9ATDP1
SCHEMBL24258053 0.85 ERCC1 (0.49) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL24258039 0.83 ERCC1 (0.45) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL26006884 0.82 ERCC1 (0.67) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL26005131 0.82 ERCC1 (0.43) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL26004927 0.80 RAB9A (0.63) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL24258023 0.80 S1PR1 (0.43) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL26004914 0.79 TDP1 (0.62) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A
SCHEMBL26004727 0.78 MAPT (0.47) ERCC1ERCC4SMN1; SMN2MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 ERCC1 2832/4885ERCC4 1843/4885SMN1; SMN2 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.